Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMNYPGS)

Drug Name
Tioconazole Drug Info
Synonyms
Fungibacid; GyneCure; Tioconazol; Tioconazolum; Trosyd; Trosyl; Vagistat; Zoniden; Trosyd AF; Trosyd J; Monistat 1; UK 20349; Gyno-trosyd; Tioconazol [INN-Spanish]; Tioconazolum [INN-Latin]; Tz-3; UK 20,349; UK-20349; Vagistat-1; Vagistat-1 (TN); Tioconazole (JAN/USP/INN); Tioconazole [USAN:BAN:INN:JAN]; (+-)-1-(2,4-Dichloro-beta-((2-chloro-3-ethenyl)oxy)phenethyl)imidazole; (+-)-1-[2-[(2-Chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; 1-(2,4-Dichloro-(beta-(2-chloro-3-thenyl)oxy)phenethyl)imidazole; 1-(2,4-Dichloro-beta-((2-chloro-3-thenyl)-oxy)phenethyl)imidazole; 1-[2-[(2-chlorothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
Therapeutic ClassAntifungal Agents
Cross-matching ID
PubChem CID
5482
ChEBI ID
CHEMBL1200438
CAS Number
CAS 65899-73-2
TTD Drug ID
D0CA6J
ACDINA Drug ID
D01488

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Epstein-Barr virus infection -1.69 1.72e-2 189/202 (93.56%) PSMD13;PSMD6;HLA-DQA1;...
Bacterial invasion of epithelial cells -1.69 1.77e-2 59/77 (76.62%) PIK3R2;GAB1;RAC1;...
Shigellosis -1.70 1.73e-2 180/246 (73.17%) ARF6;RRAGA;AKT2;...
C-type lectin receptor signaling pathway -1.71 1.74e-2 93/104 (89.42%) PIK3R2;CASP1;MAPK8;...
TNF signaling pathway -1.72 1.75e-2 103/112 (91.96%) AKT2;MAP2K3;ATF2;...
Natural killer cell mediated cytotoxicity -1.74 1.68e-2 99/131 (75.57%) KLRD1;KIR2DL1;IFNA17;...
Leukocyte transendothelial migration -1.76 1.28e-2 90/114 (78.95%) NCF4;PIK3R2;RAC1;...
Human immunodeficiency virus 1 infection -1.77 1.34e-2 189/212 (89.15%) GNB5;CFL1;CUL1;...
Phagosome -1.77 1.34e-2 118/152 (77.63%) HGS;EEA1;FCGR2B;...
Neurotrophin signaling pathway -1.77 1.40e-2 107/119 (89.92%) PIK3R2;GAB1;MAPK8;...
Coronavirus disease -1.77 1.33e-2 215/232 (92.67%) RPL9;IFNA2;RPS14;...
Tight junction -1.78 1.40e-2 130/169 (76.92%) MYL6;ROCK1;ARPC5;...
Epithelial cell signaling in Helicobacter pylori infect... -1.78 1.40e-2 62/70 (88.57%) ATP6V1A;PTPRZ1;ATP6V1D;...
Kaposi sarcoma-associated herpesvirus infection -1.78 1.48e-2 172/193 (89.12%) PDGFB;AKT2;TRADD;...
Pertussis -1.79 1.49e-2 64/76 (84.21%) CASP1;MAPK8;CXCL8;...
Endocytosis -1.82 1.12e-2 198/252 (78.57%) CXCR2;IQSEC2;SH3GL1;...
Hepatitis B -1.82 1.20e-2 151/162 (93.21%) IFNA17;CCNA2;HSPG2;...
Lipid and atherosclerosis -1.83 1.08e-2 190/215 (88.37%) NCF4;PIK3R2;CASP1;...
RIG-I-like receptor signaling pathway -1.85 1.05e-2 64/70 (91.43%) MAPK8;CXCL8;IL12A;...
Antigen processing and presentation -1.85 1.15e-2 60/78 (76.92%) KLRD1;KIR2DL1;HLA-DQA1;...
Osteoclast differentiation -1.92 5.60e-3 117/127 (92.13%) FOSL1;AKT2;FCGR2B;...
Herpes simplex virus 1 infection -1.92 6.22e-3 165/498 (33.13%) RNASEL;PIK3R2;BID;...
Prolactin signaling pathway -1.94 7.00e-3 66/70 (94.29%) GCK;INS;AKT2;...
Chagas disease -1.94 6.00e-3 93/102 (91.18%) PIK3R2;MAPK8;CALR;...
Tuberculosis -1.95 7.00e-3 159/180 (88.33%) HLA-DQA1;IFNA17;PLK3;...
Salmonella infection -1.98 8.40e-3 198/249 (79.52%) FOS;DYNC1LI2;CYFIP1;...
Influenza A -1.99 7.00e-3 156/172 (90.7%) FDPS;HLA-DQA1;IFNA17;...
Hepatitis C -2.01 9.34e-3 139/157 (88.54%) AKT2;TRADD;CLDN5;...
Measles -2.05 7.00e-3 133/139 (95.68%) AKT2;TRADD;FCGR2B;...
Pathogenic Escherichia coli infection -2.31 0.00e+0 152/197 (77.16%) RAB1A;FOS;MYO1C;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 8uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 10uM 24H